Skillz to Participate in RBC Capital Markets Technology, Internet, Media and Telecom ConferenceWed, November 10, 2021, 5:15 AM · 1 min readIn this article:
Nano Dimension Announces New DragonFly IV 3D-Printer and FLIGHT Software Package.Nano Dimension Ltd.Mon, November 8, 2021, 9:00 PM · 5 min readIn this article:
Nano Dimension Acquires Essemtec AG, Surface-Mount Pick & Place Systems Supplier for the PCB and OEM IndustriesGlobeNewswire2021-11-03 13:00Nano Dimension+0.86%Post
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of Ocugen’s COVID-19 vaccine candidate BBV152, known as COVAXIN™ outside of the U.S., for pediatric use. The vaccine candidate was developed by the company’s partner, Bharat Biotech, and was studied in an immuno-bridging clinical trial conducted in India with children 2-18 years of age
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of Ocugen’s COVID-19 vaccine candidate BBV152, known as COVAXIN™ outside of the U.S., for pediatric use. The vaccine candidate was developed by the company’s partner, Bharat Biotech, and was studied in an immuno-bridging clinical trial conducted in India with children 2-18 years of age
BRIEF-Aldeyra Therapeutics Announces Achievement Of Primary Endpoint Of Ocular Redness In Mid-Stage Study In Dry Eye DiseaseReuters2021-11-02 20:06Aldeyra Therapeutics-7.47%